Lilly wins reversal on US Zyprexa class action
This article was originally published in Scrip
Executive Summary
Lilly has won an important legal victory, as a federal appeals court has reversed a ruling that granted class-action status to a suit brought by pension funds, unions and insurers alleging that the company misrepresented the safety and side effects of Zyprexa (olanzapine) to physicians and thus caused them to pay a higher price for the drug, or pay for prescriptions that otherwise should not have been issued.